Alyeska Investment Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Alyeska Investment Group’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-87,782	Closed	-$2.14M	–	642
2023 Q1	$2.14M	Hold	87,782	–	–	0.02%	350
2022 Q4	$2.77M	Hold	87,782	–	–	0.03%	301
2022 Q3	$2.48M	Buy	+87,782	New	+$2.61M	0.03%	310
2022 Q2	–	Sell	-105,000	Closed	-$3.68M	–	682
2022 Q1	$3.68M	Buy	+105,000	New	+$3.07M	0.04%	339
2021 Q4	–	Sell	-424,767	Closed	-$12.5M	–	758
2021 Q3	$12.5M	Sell	424,767 -399,622	-48%	-$11.2M	0.16%	166
2021 Q2	$21.1M	Sell	824,389 -188,091	-19%	-$2.69M	0.24%	123
2021 Q1	$13.9M	Sell	1,012,480 -329,005	-25%	-$4.81M	0.18%	160
2020 Q4	$22.2M	Buy	1,341,485 +1,125,032	+520%	+$14.6M	0.31%	98
2020 Q3	$2.26M	Buy	+216,453	New	+$2.28M	0.03%	339

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Alyeska Investment Group's CERE Position: Q2 2023 in Review

Alyeska Investment Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2023, closing a stake of 87,782 shares — an estimated $2.14M sold.

Alyeska Investment Group first reported a position in CERE in Q3 2020 and held it in 9 quarters. The position peaked at $22.2M in Q4 2020. 125 funds tracked by Wall St. Rank hold CERE as of Q2 2023.

Alyeska Investment Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Alyeska Investment Group sold 87,782 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2023, an estimated $2.14M.
Alyeska Investment Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
Alyeska Investment Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $22.2M in Q4 2020.
125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2023.

Based on Alyeska Investment Group's 13F filing for Q2 2023, filed 14 Aug 2023.